|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1 Pt 1
|
|
pubmed:dateCreated |
2004-1-21
|
|
pubmed:abstractText |
KIT (CD117) is a transmembrane tyrosine kinase representing a target for STI571 (Glivec) therapy. Some KIT-overexpressing solid tumors have responded favorably to STI571, potentially because of the presence of KIT-activating mutations.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
178-83
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:14734467-Adult,
pubmed-meshheading:14734467-Aged,
pubmed-meshheading:14734467-Aged, 80 and over,
pubmed-meshheading:14734467-Breast,
pubmed-meshheading:14734467-Breast Neoplasms,
pubmed-meshheading:14734467-DNA, Neoplasm,
pubmed-meshheading:14734467-DNA Mutational Analysis,
pubmed-meshheading:14734467-Epithelium,
pubmed-meshheading:14734467-Female,
pubmed-meshheading:14734467-Humans,
pubmed-meshheading:14734467-Immunoenzyme Techniques,
pubmed-meshheading:14734467-Middle Aged,
pubmed-meshheading:14734467-Mutation,
pubmed-meshheading:14734467-Neoplasm Staging,
pubmed-meshheading:14734467-Prognosis,
pubmed-meshheading:14734467-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:14734467-Retrospective Studies,
pubmed-meshheading:14734467-Survival Rate
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.
|
|
pubmed:affiliation |
Institute of Pathology, University of Basel, Basel, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
